Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Sep-Oct;47(4):325-30.
doi: 10.1080/02791072.2015.1075092. Epub 2015 Aug 28.

Evaluating the Effects of Varenicline on Craving, Withdrawal, and Affect in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline for Smokeless Tobacco Dependence in India

Sonali Jhanjee  1 , Raka Jain  1 , Veena Jain  2 , Tina Gupta  1 , Swati Mittal  1 , Patricia Goelz  3 , Robert A Schnoll  3
Affiliations
Clinical Trial

Evaluating the Effects of Varenicline on Craving, Withdrawal, and Affect in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline for Smokeless Tobacco Dependence in India

Sonali Jhanjee et al. J Psychoactive Drugs. 2015 Sep-Oct.

Abstract

This study examined changes in tobacco craving, withdrawal, and affect as correlates of efficacy in a phase-2 clinical trial of varenicline for smokeless tobacco dependence in India. Smokeless tobacco users (N = 237) at the All India Institute of Medical Sciences were randomized to placebo or varenicline. Abstinence was defined as cotinine-verified seven-day point prevalence cessation at end of treatment (EOT). General Linear Model repeated measures assessed the effects of treatment condition, time, abstinence state, and interaction effects on changes in craving, withdrawal, positive (PA) and negative affect (NA) from baseline to EOT. All participants showed a significant reduction in withdrawal (p < .001), total craving (p < .001), positive reinforcement (PR) craving (p < .001), and NA (p = .02), and an increase in PA (p = .04) from baseline to EOT. However, there were no differences between placebo and varenicline participants in measures of withdrawal, craving, or affect from baseline to week 3 or at EOT. Significant interactions between time and abstinence state were found for total craving (p = .008), PR craving (p < .001), and withdrawal (p = .001), indicating reductions in these processes among those abstinent vs. those still chewing smokeless tobacco. Additional research is needed concerning the effects of varenicline on craving, withdrawal, and affect among smokeless tobacco users.

Trial registration: ClinicalTrials.gov NCT01098305.

Keywords: intervention; smokeless tobacco; treatment; varenicline.

PubMed Disclaimer

References

    1. Allen S, Bade T, Hatsukami D, Center B. Craving, Withdrawal, and Smoking Urges on Days immediately Prior to Smoking Relapse. Nicotine & Tobacco Research. 2010;10(1):35–45. doi: 10.1080/14622200701705076. - DOI - PubMed
    1. Araujo RB, Oliveira MS, Mansur MA. Brazilian validation of the Questionnaire of Smoking Urges. Cadernos de Saúde Pública. 2006;22:2157–67. doi: 10.1590/S0102-311X2006001000022. - DOI - PubMed
    1. Benowitz NL, Jacob P, Ahijevych K, Jarvis MJ, Hall S, LeHouezec J, Velicer W. Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research. 2002;4:149–59. doi: 10.1080/14622200210123581. - DOI - PubMed
    1. Boyle RG. Smokeless tobacco cessation with nicotine replacement: A randomized clinical trial. Dissertation Abstracts International. 1992;54(3-A):825.
    1. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine & Tobacco Research. 2001;3(1):7–16. doi: 10.1080/14622200124218. - DOI - PubMed

Publication types

Associated data

LinkOut - more resources